Biosimilars: Company Strategies to Capture Value from the Biologics Market

@inproceedings{CaloFernndez2012BiosimilarsCS,
  title={Biosimilars: Company Strategies to Capture Value from the Biologics Market },
  author={Bruno Calo-Fern{\'a}ndez and J. L. Martinez-Hurtado},
  booktitle={Pharmaceuticals},
  year={2012}
}
Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
22 Extracted Citations
37 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 22 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 37 references

Mega-Mergers: Are they Turning Pharma Companies into Zombies

  • N. J. Campbell
  • Pharma Focus Asia 2009,
  • 2009
Highly Influential
10 Excerpts

on Similar Medicinal Products Containing Recombinant Human Soluble Insulin

  • EMA. Guideline
  • Technical report, European Medical Agency…
  • 2012
Highly Influential
4 Excerpts

Emerging Healthcare Issues: Follow-on Biologic Drug Competition

  • M. S. Wroblewski
  • Technical report, Federal Trade Commission,
  • 2009
Highly Influential
3 Excerpts

on Similar Medicinal Products Containing Somatropin

  • EMA. Guideline
  • Technical report, Euopean Medical Agency, Uppsala…
  • 2006
Highly Influential
4 Excerpts

Despite global downturn, generics makers stand to reap great rewards in China’s evolving pharmaceutical market

  • M. Chui
  • J. Generic Med. Bus. J. Generic Med. Sector 2009,
  • 2012
1 Excerpt

Inquiry Preliminar Report

  • DGC. Pharmaceutical Secto
  • Technical report, European Commission, Brussel…
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…